Terumo Corporation (TYO:4543)
Japan · Delayed Price · Currency is JPY | Market Cap | 3.38T -16.1% |
| Revenue (ttm) | 1.13T +9.2% |
| Net Income | 135.91B +16.2% |
| EPS | 92.12 +16.6% |
| Shares Out | 1.48B |
| PE Ratio | 24.90 |
| Forward PE | 20.60 |
| Dividend | 30.00 (1.31%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 10,286,300 |
| Average Volume | 6,081,275 |
| Open | 2,320.00 |
| Previous Close | 2,294.00 |
| Day's Range | 2,297.00 - 2,349.00 |
| 52-Week Range | 1,900.00 - 2,818.00 |
| Beta | n/a |
| RSI | 70.75 |
| Earnings Date | May 15, 2026 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and ... [Read more]
Financial Performance
In fiscal year 2026, Terumo's revenue was 1.13 trillion, an increase of 9.24% compared to the previous year's 1.04 trillion. Earnings were 135.91 billion, an increase of 16.19%.
Financial StatementsNews
Full Year 2026 Terumo Corp Earnings Presentation Transcript
Full Year 2026 Terumo Corp Earnings Presentation Transcript
Terumo Earnings Call Transcript: Q4 2026
Record revenue and profit achieved in FY 2025, driven by strong North American growth and strategic investments. FY 2026 guidance anticipates further record highs, with profit growth outpacing revenue due to the absence of one-time expenses and continued expansion in high-margin segments.
Terumo Quarterly report: Q4 2026
Terumo has published its Q4 2026 quarterly earnings report on May 15, 2026.
Terumo Slides: Q4 2026
Terumo has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Terumo Earnings Call Transcript: Q3 2026
Record-high revenue and profits were achieved, driven by strong North American demand and effective pricing strategies that offset tariffs and FX headwinds. Acquisitions of Leverkusen Plant and OrganOx contributed to results, and the company remains on track to meet GS 2026 targets.
Terumo Quarterly report: Q3 2026
Terumo has published its Q3 2026 quarterly earnings report on February 13, 2026.
Terumo Slides: Q3 2026
Terumo has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Terumo Transcript: 44th Annual J.P. Morgan Healthcare Conference
Global sales growth is driven by innovation in vascular access, CDMO, and blood technologies, with a focus on margin expansion and strategic M&A. OrganOx acquisition is expected to deliver high double-digit growth and significant market impact, while U.S., Japan, China, and India remain key markets.
Terumo Slides: 44th Annual J.P. Morgan Healthcare Conference
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Terumo Earnings Call Transcript: Q2 2026
Record first-half revenue and profits were achieved, driven by strong North American demand, pricing measures, and cost control. Full-year guidance was revised upward, with strategic investments and the Organox acquisition expected to fuel further growth.
Terumo Quarterly report: Q2 2026
Terumo has published its Q2 2026 quarterly earnings report on November 12, 2025.
Terumo Slides: Q2 2026
Terumo has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
Terumo Transcript: M&A Announcement
The acquisition of OrganOx for $1.5 billion enables entry into the high-growth organ transplantation market, leveraging innovative NMP technology to address unmet needs and expand into new domains. Synergies, cost advantages, and a strong strategic fit are expected to drive long-term growth.
Terumo Press release: M&A Announcement
Terumo issued a press release on August 27, 2025, disclosing material business information to investors.
Terumo Slides: M&A Announcement
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on August 27, 2025.
Terumo Earnings Call Transcript: Q1 2026
Preparations for the Lacanbi auto injector launch are progressing, with cardiovascular growth led by volume and sustainable price increases. Significant compensation was received for a prior project cancellation, and China neuro sales rose due to VBP volume commitments.
Terumo Quarterly report: Q1 2026
Terumo has published its Q1 2026 quarterly earnings report on August 7, 2025.
Terumo Slides: Q1 2026
Terumo has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 7, 2025.
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.